|1.||Staels, Bart: 5 articles (12/2013 - 04/2006)|
|2.||Weisgraber, Karl H: 5 articles (01/2011 - 08/2005)|
|3.||Havekes, Louis M: 5 articles (05/2009 - 02/2002)|
|4.||van Dijk, Ko Willems: 5 articles (05/2009 - 02/2003)|
|5.||Raber, Jacob: 4 articles (09/2015 - 06/2002)|
|6.||Bu, Guojun: 4 articles (01/2015 - 01/2014)|
|7.||Matsunaga, Akira: 4 articles (01/2014 - 11/2006)|
|8.||Maeda, Nobuyo: 4 articles (06/2008 - 01/2006)|
|9.||Kypreos, Kyriakos E: 4 articles (05/2008 - 02/2003)|
|10.||Nicoll, J A: 4 articles (07/2001 - 01/2000)|
04/26/1996 - "Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136-->Ser) variant in multigenerational pedigree studies."
07/01/2013 - "The lipid profiles showed type III hyperlipoproteinemia and phenotypic/genetic analyses revealed homozygosity of apoE2. "
01/01/2011 - "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform is encoded by the R158C allele. "
05/01/2010 - "Homozygosis for APOE2 (E2-E2) is related to an increased incidence of type III hyperlipoproteinemia (HLP). "
08/01/2002 - "Apo E2/2 nondiabetic subjects had type III hyperlipoproteinemia (HLP). "
|2.||Alzheimer Disease (Alzheimer's Disease)
07/01/1997 - "These binding studies provide one possible explanation for protective effects of both apoE2 and E3 against the development of Alzheimer's disease."
06/04/1994 - "Protection against Alzheimer's disease with apoE epsilon 2."
01/01/2009 - "The objective of this study was to describe a case of Alzheimer's disease in an ApoE epsilon2/epsilon2 homozygote. "
03/03/1995 - "This study provides further evidence that sequence variations in the prion gene can modify disease pathology and the neuroprotection afforded by Apo E2 is not confined to Alzheimer's disease."
11/01/2014 - "The common APOE2 gene variant is neuroprotective against Alzheimer's disease (AD) and reduces risk by nearly 50%. "
10/12/2000 - "To assess whether muscle-based expression of apoE2 could inhibit atherogenesis, long-term follow-up studies were conducted. "
03/01/1999 - "Conversely, expression of apoE2 in NZW rabbits caused increased susceptibility to atherosclerosis. "
09/05/1997 - "Therefore, high plasma levels of human apoE2 in transgenic rabbits result in a type III HLP phenotype, in which males have both more severe hyperlipidemia and more extensive atherosclerosis than females."
01/01/2008 - "The objective of this study was to investigate the influence of the APOE promoter (-491 A/T, -427 T/C and -219 G/T) and coding region (APOE epsilon2/epsilon3/epsilon4) polymorphisms in atherosclerosis disease by association and linkage disequilibrium analyses. "
12/01/2006 - "Here, we investigated the effect of bexarotene on atherosclerosis progression in a dyslipidemic murine model, the human apolipoprotein E2 knockin mouse, that develops essentially macrophage-laden lesions. "
05/01/2008 - "Apolipoprotein E2 (apoE2)-associated hyperlipidemia is characterized by a disturbed clearance of apoE2-enriched VLDL remnants. "
02/24/2011 - "60 patients with type III hyperlipidemia and ApoE2/2 genotype were included in the study after informed consent. "
11/01/2008 - "Anticoagulant effect of dietary fish oil in hyperlipidemia: a study of hepatic gene expression in APOE2 knock-in mice."
02/24/2011 - "However only about 10% of subjects with APOE2/2 genotype develop hyperlipidemia and it is therefore assumed that further genetic and environmental factors are necessary for the expression of disease. "
05/01/2009 - "The HTG patients showed similar allele frequencies of the APOA5, APOC3 and LPL polymorphisms, whereas the NDCP showed similar allele frequencies as the normolipidemic APOE2/2. Patients with the APOC3 3238 G>C/APOA5 -1131 T>C polymorphism showed a more severe hyperlipidemia than patients without this polymorphism. "
08/01/2007 - "A 92-year-old woman without dementia with the APOE epsilon2/epsilon2 genotype who lived independently without significant cognitive or functional loss and was a participant in The 90+ Study. "
03/03/2009 - "This would predict, even with advanced age, that APOE2 carriers would be less likely to have dementia and less likely to meet pathologic criteria for AD. "
01/22/2002 - "In conclusion, both the APOE epsilon2/epsilon3/epsilon4 and the -219G/T variant were identified as risk factors for dementia but not cardiovascular mortality in old age. "
01/22/2002 - "Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age."
03/28/2000 - "In the elderly the APOE-epsilon2 allele increases the risk of PD and, in particular, the risk of PD with dementia."
|2.||Apolipoproteins E (ApoE)
|5.||LDL Receptors (LDL Receptor)
|9.||Choline (Choline Chloride)
|10.||Non-alcoholic Fatty Liver Disease
|1.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|2.||Estrogen Replacement Therapy